Efficacy and safety of prehospital administration of tranexamic acid (TXA) for trauma patients

Not Applicable

• Conditions: Trauma

• Registration Number: JPRN-UMIN000041854
• Lead Sponsor: Department of Emergency and Critical Care Medicine, Nippon Medical School

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-09-21
• Study Completion: 2023-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 34

Inclusion Criteria

Not provided

Exclusion Criteria

1. Patients with a history of hypersensitivity to TXA 2. Patients with diseases (liver disease, hematological diseases, infections, malignant neoplasms, pregnancy) that affect the coagulation fibrinolytic parameters.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Mortality at 28 days

Secondary Outcome Measures

Name	Time	Method
mRS at 3 months, volume of transfusion, coagulation fibrinolytic parameters (prothrombin time (PT), activated partial thromboplastin time (aPTT), Fibrinogen, thrombin-antithrombin complex (TAT), FDP, D-dimer, alpha 2 plasmin inhibitor (alpha 2-PI), plasmin-alpha 2 plasmin inhibitor complex (PIC), plasminogen activator inhibitor 1 (PAI-1), t-PA-PAI-1 complex)